API Holdings, the parent company of Pharmeasy and Thyrocare, reported a narrower loss of Rs 29.6 crore in Q1 FY27 compared with a loss of Rs 145.4 crore a year earlier, according to its investor presentation, as it tightened costs and focussed on debt reduction. The figure excludes Esop costs.
The company’s Ebitda (earnings before interest, tax, depreciation, and amortisation) was Rs 39.3 crore in Q1, compared to an Ebitda loss of Rs 12.8 crore in the year-ago quarter. The results come days after the company announced that it had repaid Rs 1,050 crore of outstanding debt, becoming debt-free after years of pressure on its balance sheet following the acquisition of the diagnostics chain Thyrocare.
